28 March 2017 - Eisai announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house developed anticancer agent Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma compared to everolimus alone in its assessment for insurance reimbursement. 

Based on this additional benefit assessment, price negotiations with the Head Association of German Sick Funds (GKV-SV) will be conducted, and a reimbursement price has to be agreed.

Read Eisai press release